Vera Therapeutics, Inc. Class A Common Stock (VERA) Stock Price
VERAStock
$34.19+53.39%52W
Market Cap$2.46B
P/E—
PEG Ratio—
Div yield—
Beta0.99
VERA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-31.24%
Price vs S&P 500 (4W)4.54%
VGM Score58.01
VERA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.59 | -$1.52 | +4.45%(+$0.07) | |
| Q1 2026 | -$1.37 | -$1.69 | -23.00%(-$0.32) | |
| Q4 2025 | -$1.27 | -$1.39 | -9.74%(-$0.12) | |
| Q3 2025 | -$1.18 | -$1.26 | -7.09%(-$0.08) | |
| Q2 2025 | -$0.62 | -$1.20 | -94.77%(-$0.58) |
VERA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VERAVera Therapeutics, Inc. Class A Common Stock | — | — | C | $34.19 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Vera Therapeutics, Inc. Class A Common Stock
Vera Therapeutics is a clinical-stage biotech company developing atacicept, a once-weekly subcutaneous fusion protein designed to treat serious autoimmune diseases. The drug works by blocking two key drivers of autoimmune dysfunction—B lymphocyte stimulator and APRIL—which reduces B cell and plasma cell activity and autoantibody production. The company is advancing atacicept through clinical development with a focus on transformative therapeutic potential in immunological disorders.